Pharmaceutical industry

Pharmaceutical Industry in Slovenia in 2024

Slovenia has implemented therapeutic reference pricing schemes, similar to other EU member states, which significantly affect brand-name pharmaceutical producers. This article includes several aspects of the Slovenian pharmaceutical industry that could appear as inherent issues. Yet, these are business opportunities for those who think futuristically. 

Lek and Krka, two local domestic generic producers, have historically held significant positions in the Slovenian pharmaceutical market, particularly in Central and Eastern Europe. The Slovenian pharmaceutical market is facing heightened competition from foreign players, who are challenging the historical dominance of local producers.

Image source: Jozef Stefan Institute, Slovenia

Slovenia's Jozef Stefan Institute is a top research institution specialising in chemical and pharmaceutical R&D, with a particular focus on therapeutic nanotechnology and biotechnology products. Slovenia's pharmaceutical sector, despite its historical dominance by local producers, is now experiencing increased competition and growth prospects.

Pharmaceutical Industry in Slovenia

Market Size and Spending

In 2022, Slovenia spent EUR 679.5 million on pharmaceuticals, with an average per citizen of EUR 679.5, and the Ministry of Health plays a crucial role in managing costs. Experts predict a 7% annual growth in the pharmaceutical market over the next two years, primarily due to increased life expectancies and private healthcare insurance growth.

Image source: Total value of pharmaceutical sales in Slovenia from 2010 to 2022 (in million euros)

Pharmaceutical Spending in Slovenia: In 2022, Slovenia allocated around EUR 679.5 million to pharmaceuticals, covering a wide range of medications and treatments available in the country.

Average Spending per Slovenian Citizen on Prescription Medications: On average, Slovenian citizens spend around EUR 322 annually on prescription medications, reflecting the cost of purchasing and using prescribed drugs.

Role of the Ministry of Health (MOH) in Managing Costs: The Ministry of Health is a crucial player in Slovenia's health system, overseeing policy review, supervision, resource mobilisation, regulation, health assurance, and cost management, ensuring quality, compliance, fair access, and affordability of healthcare services. The Ministry of Health is actively managing healthcare costs to ensure quality services and financial sustainability.

Regulatory Environment 

Therapeutic reference pricing schemes have significantly impacted brand-name pharmaceutical producers, predicting growth despite challenges. Slovenia's regulatory environment includes key environmental policy and enforcement aspects.

Let's delve into the details:

Environmental Policy and Enforcement: Slovenia's environmental policy is guided by sustainable development, precaution, and the 'polluter pays' principle, with the Ministry of Natural Resources and Space managing nature conservation, the Environment, Climate, and Energy handling environmental protection, and the Slovenian Environment Agency supporting national environmental tasks.

Image source: Save the Planet

Enforcement Approach: Inspectorates within ministries enforce regulations, such as those for Natural Resources and Space and Environment and Energy, focusing on environmental protection, industrial pollution, and cross-border waste shipment.

Public Access to Information: Public authorities are obligated to provide environmental information to all interested parties, including the public.

Slovenia is predicting growth despite facing challenges such as bureaucratic procedures and regulatory complexities. 

Key Players

The success of Krka and Lek, the rise of foreign pharmaceutical companies, and the involvement of research institutions and biotech companies are significant factors. Let's delve into the key players in the pharmaceutical landscape:

Krka and Lek: Slovenian pharmaceutical companies Krka and Lek have established market dominance, with Krka renowned for generic drugs and Lek significantly contributing to research and development.

Foreign Pharmaceutical Companies: International players have significantly impacted the industry by introducing diverse expertise, innovative products, and a global reach, fostering healthy competition and driving advancements.

Research Institutions and Biotech Companies: Research institutions and biotech companies play a crucial role in scientific knowledge, drug discovery, and clinical trials, with a focus on biologics and personalised medicine.

Challenges Faced by the Slovenian Pharmaceutical Industry

Slovenia's pharmaceutical industry faces numerous challenges in a competitive market and is striving for growth. Here are some key challenges:

Market Competition: Slovenia's pharmaceutical market, once dominated by local generic producers Lek and Krka, is now open to foreign competition, posing challenges for local manufacturers.

Therapeutic Reference Pricing Schemes: Slovenia, like other EU member states, has implemented therapeutic reference pricing schemes, which pose challenges for brand-name pharmaceutical producers in the market.

Import Dependency: Slovenia's pharmaceutical market is heavily reliant on imports, with imported drugs accounting for nearly 16% of total healthcare spending, affecting overall market dynamics.

Image source: Global Pharmaceuticals Market 2023

Healthcare Spending and Consumption: Slovenia spent EUR 679.5 million on pharmaceuticals in 2022, with an average annual expenditure of EUR 322 on 9 prescription medications, a higher rate than the EU average.

Regulatory Complexity: The approval process for new drugs is complex and time-consuming while ensuring regulatory compliance and quality standards is essential yet challenging.

Balancing Cost Containment and Innovation: The Ministry of Health is responsible for managing healthcare costs and proposing the government's budget, but balancing cost containment with innovation remains a challenge.

Research and Development: Slovenia's Jozef Stefan Institute is a leading research institution focused on chemical and pharmaceutical R&D, with a particular emphasis on therapeutic nanotechnology and biotechnology products.

To tackle these challenges in Slovenia's pharmaceutical sector, collaboration, innovation, and strategic planning are crucial.

Unethical Practices 

The pharmaceutical industry, including the Slovenian pharma sector, has faced ethical challenges. Here are some notable concerns:

Unethical Marketing Practices: Pharmaceutical companies are facing criticism for using controversial marketing techniques, including leveraging medical opinion leaders and patient advocacy groups, and their marketing is often self-regulated by industry trade groups, potentially causing conflicts of interest.

Pharmaceutical companies are accused of using unethical marketing techniques, including manipulating Medical Opinion Leaders (MOLs) to promote their products, collaborating with patient advocacy groups to undermine patient interests, and off-label promotion for unapproved uses, which can lead to biased recommendations and overprescription, and potentially harm patients.

Image source: Drug pricing

Drug Pricing and Access: Drug pricing is high, affecting vulnerable groups' access to essential medications. Subsidies often come from citizens' taxes, making fair pricing and equitable access challenging. Evergreening, the legal modification of a drug's patent life, can delay generic competition and maintain high prices. Balancing profit motives with public health needs remains a challenge. The pharmaceutical industry also has environmental impacts like waste generation and energy consumption.

Transparency and Disclosure: Companies often lack transparency in product disclosure, limiting consumers' understanding of environmental impact, sourcing practices, and ethical considerations in pharmaceuticals.

Environmental Impact: The pharmaceutical industry globally faces environmental challenges, including waste generation, energy consumption, and water usage during drug production, which is not unique to Slovenia.

Balancing Profit and Public Health: Companies must balance profit motives with public health, and ethical decision-making should consider both financial interests and patient well-being.

Research Ethics: Ethical conduct in clinical trials and research studies is crucial, requiring transparency, informed consent, and protection of participants' rights.

Gifts and Incentives to Healthcare Professionals: Companies often offer gifts, incentives, or sponsorships to healthcare professionals, emphasising the importance of balancing professional relationships with ethical standards.

Supply Chain Practices: Ethical raw material sourcing and responsible supply chain management are crucial while ensuring fair labour practices and environmental stewardship is a significant challenge.

Labor Practices in Slovenia, Image source:

Intellectual Property and Access to Medicines: The ongoing debate revolves around the balance between intellectual property rights and the need for affordable access to life-saving medications.

Ethical Leadership and Accountability: Strong ethical leadership is crucial for companies to establish a culture of integrity, and holding organisations accountable for unethical practices is essential.

Literature: Pharmaceutical companies use ghostwriting to create research articles or reviews, potentially deceiving the medical community and influencing clinical practice. Biased research funded by companies can lead to inappropriate prescribing practices and patient harm. Companies can significantly influence clinical trials, emphasising the importance of transparency and independence in ethical clinical research.

Ethical conduct, transparency, and accountability are essential for building trust and ensuring patient well-being. Consumers can promote ethical behaviour in the pharmaceutical sector by advocating for transparency, supporting responsible companies, and engaging in ethical discussions.

RELATED: Quantifying the India-Slovenia Partnership for Pharmaceutical Business in 2024

Slovenian Government Support for the Pharmaceutical Industry

The Slovenian government is actively involved in promoting the pharmaceutical industry through various policies and initiatives. Here are some ways in which the government supports this vital sector:

Healthcare Policies and Budget Proposals: The Slovenian Ministry of Health is the main player in the pharmaceutical market, responsible for developing healthcare policies, proposing budgets, and monitoring national healthcare spending to ensure low medical costs.

Therapeutic Reference Pricing Schemes: Slovenia has implemented therapeutic reference pricing schemes, similar to EU member states, aiming to balance affordability and access to essential medications for brand-name pharmaceutical producers.

Research and Development Support: Slovenia's Jozef Stefan Institute is a leading research institution focused on chemical and pharmaceutical R&D, with a focus on therapeutic nanotechnology and biotechnology products.

Image source: R&D in the pharmaceutical industry

Attracting Foreign Investment: The government is promoting foreign investment in the pharmaceutical industry, aiming to elevate the sector up the value chain and foster business growth and development.

Skilled Workforce and Education: Slovenia's government supports educational institutions for pharmaceutical science training, fostering a skilled workforce and investing in human capital for industry growth.

Tax Incentives and Regulatory Support: The Slovenian government provides tax incentives to encourage pharmaceutical companies to invest and operate, while regulatory frameworks are designed to facilitate business operations and compliance.

Collaboration with Industry Stakeholders: The government, in collaboration with industry associations, research institutes, and private companies, fosters innovation, knowledge exchange, and sustainable growth through public-private partnerships.

The Slovenian government is actively supporting the pharmaceutical industry by creating an enabling environment, promoting research, and ensuring affordable healthcare for its citizens.

Collaboration and Innovation 


The rise in private healthcare insurance and increased life expectancies are driving the development of cancer medications, cardiovascular drugs, and biotechnological products.

Oncology advancements offer novel cancer therapies like targeted treatments, immunotherapies, and precision medicine, improving patient outcomes by utilising personalised drugs based on genetic profiles. Cardiovascular diseases pose global health challenges, necessitating innovative drugs for prevention, management, and treatment, with cardio-oncology focusing on managing cancer side effects.

Image source: Cardiovascular diseases

Biotechnology is crucial for drug discovery and development, offering opportunities in biologics, gene therapies, and cell-based treatments, with advancements in genomics, proteomics, and bioinformatics identifying new drug targets. Expanding private health insurance coverage allows pharmaceutical companies to expand their patient base, adjust drug pricing, and collaborate with insurers for cost-effective healthcare.

Geriatric medicine focuses on developing age-appropriate medications and dosage forms for managing chronic conditions, with research on age-related diseases potentially leading to breakthrough treatments.

Major Therapeutic Areas in Slovenia's Pharmaceutical Market

Let's explore the major therapeutic areas in Slovenia's pharmaceutical market:

Cardiovascular Illnesses: Slovenia is a major market for cardiovascular medications, including hypertension and heart disease treatments, to address the country's significant cardiovascular health issues.

Cancer Treatments: The demand for innovative cancer treatments is increasing due to the advancements in the field of oncology.

Psychotherapy Pharmaceuticals: Medications like antidepressants, anxiolytics, and antipsychotics are crucial for mental health, and addressing these conditions is a top priority.

AIDS Medications: Slovenia acknowledges the significance of antiretroviral drugs in managing HIV/AIDS, as these medications enhance patients' quality of life and longevity.

Supplements: Nutritional supplements and vitamins are essential for overall health, and the market for dietary supplements is expanding rapidly.

Slovenia's competitive pharmaceutical market prioritises cost-effective solutions and therapeutic pricing schemes, with the Jozef Stefan Institute contributing to chemical and pharmaceutical research, including therapeutic nanotechnology and biotechnology products.

Research and Development

The Jozef Stefan Institute, a leading institution in the pharmaceutical research and development sector, is collaborating with chemical and pharmaceutical companies to develop therapeutic nanotechnology and biotechnology products.

Jozef Stefan Institute (JSI): JSI, a leading institution in chemical and pharmaceutical R&D, is crucial in connecting fundamental science with practical applications, shaping the future of the industry.

Image source: Nanotechnology

Therapeutic Nanotechnology: JSI's therapeutic nanotechnology focuses on designing nanoparticles, liposomes, and other nanostructures for drug delivery, improving stability, bioavailability, and targeted tissue delivery for precision medicine.

Biotechnology Products: JSI's biotechnology research focuses on biologics, gene therapies, personalised medicine, protein engineering, genomics, and stem cell applications, offering promising treatments for untreatable diseases.

ALSO READ: Economy of Slovenia | Why is Slovenia So Rich?

Addressing Global Environmental Challenges

Collaboration promotes a culture of continuous improvement, thereby enhancing the sustainability of the Slovenian pharmaceutical industry. By working together, companies can contribute to a more sustainable future. Here are some ways they can collaborate:

Industry Partnerships and Alliances: Companies can form industry-specific partnerships and alliances focusing on environmental sustainability, which promote knowledge sharing, joint initiatives, and collective action.

Sharing Best Practices: Companies should actively share their successful environmental practices through case studies, workshops, and conferences to foster learning and collaboration.

Image source: Supply chain management

Supply Chain Engagement: The goal is to enhance collaboration across the entire supply chain and promote sustainable practices among suppliers and distributors.

Joint Research and Innovation: Collaborate on environmental technology research projects and pool resources to develop innovative solutions.

Policy Advocacy: Companies can advocate for environmentally friendly policies by working together with policymakers to influence regulations and incentives.

Resource Efficiency Programs: Companies can participate in resource efficiency programs, which aim to decrease waste, energy consumption, and water usage.

Circular Economy Initiatives: The industry is promoting circular economy principles by exploring opportunities for product design, recycling, and waste reduction.

Climate Action Commitments: Companies can align with global climate goals, such as Net Zero commitments, and collaborate on emissions reduction strategies.

Transparency and Reporting: The policy emphasises the transparency of sharing environmental performance data and the regular reporting of progress towards sustainability goals.

Learning from Other Sectors: Collaborating with diverse companies can foster cross-sectoral knowledge exchange, resulting in the development of innovative solutions.

Collaboration accelerates progress, driving positive change and contributing to a greener Slovenia and a healthier planet.

Companies Addressing Environmental Concerns

Pharmaceutical companies in Slovenia are increasingly recognising the importance of environmental sustainability and taking steps to address environmental concerns. We highlight some ways they contribute to a greener and more sustainable industry.

Waste Reduction and Recycling Programs: Slovenian pharmaceutical companies are implementing comprehensive waste reduction and recycling programs to reduce waste generation in various stages of production and operational processes.

Energy Efficiency Measures: Companies are enhancing their energy efficiency by optimising manufacturing processes, utilising energy-efficient equipment, and reducing facility energy consumption.

Image source: Eco-friendly packaging

Green Packaging and Materials: Companies are focusing on eco-friendly packaging options, focusing on recyclable and biodegradable materials to reduce the environmental impact of packaging waste.

Water Conservation: Pharmaceutical manufacturing is implementing water-saving technologies and practices to reduce water consumption during production, as water is a crucial resource.

Eco-Friendly Manufacturing Practices: Companies are transitioning to cleaner production methods, utilising greener solvents, reducing emissions, and adhering to strict environmental regulations.

Collaboration with Research Institutes: Companies collaborate with research institutions and universities to explore innovative solutions in sustainable drug development, green chemistry, and eco-friendly processes.

Public Awareness and Education: Companies conduct awareness campaigns and training programs to educate employees and the public about environmental responsibility, emphasizing sustainable practices and waste management.

Certifications and Compliance: Companies prioritise compliance with environmental regulations and seek certifications like ISO 14001 to ensure their environmental management systems are effective.

Supply Chain Sustainability: Companies evaluate the environmental impact of their entire supply chain, assessing suppliers' practices and promoting sustainable sourcing.

Innovation for Environmental Solutions: Some companies invest in research and development for environmental solutions, including green technologies and eco-friendly formulations.

Slovenia's pharmaceutical industry is incorporating environmental stewardship into its operations despite facing challenges.

Consumer Support for Green Initiatives

Consumers in Slovenia are crucial in supporting green initiatives in the pharmaceutical sector by making informed choices and advocating for sustainability.

Here are ways consumers can actively support green initiatives:

Choose medications with lower environmental impact, considering production methods, packaging, and disposal. Consult your healthcare provider about greener alternatives during treatment discussions. Properly dispose of expired or unused medications following local guidelines to prevent water contamination and avoid flushing them down the toilet or 

Research pharmaceutical companies' sustainability efforts, choosing products from environmentally responsible ones, focusing on their carbon footprint, waste reduction, and eco-friendly packaging. The initiative promotes transparency in companies' environmental practices and supports initiatives that encourage reporting and disclosure of sustainability efforts.

Image source: Bio-medical waste management

Encourage sustainable healthcare practices by sharing information on social media, participating in discussions, and encouraging eco-conscious choices among friends and family. Engage in patient advocacy groups and express your support for sustainable practices during discussions with healthcare providers and policymakers.

The environmental impact of medications is a critical aspect of their lifecycle, encompassing their extraction, manufacturing, distribution, use, and disposal. Advocate for research and development of environmentally friendly drug delivery systems encourage investment in technologies that minimise waste and energy consumption.

Stay informed about pharmaceutical sustainability news and developments, stay informed about industry trends, and embrace new innovations. Choose medications with minimal packaging or those made from recyclable materials and dispose of packaging responsibly.

Individual actions collectively contribute to a greener pharmaceutical industry, and conscious choices by consumers can drive positive change and promote sustainability in Slovenia's healthcare sector.

Role of Technology in the Pharmaceutical Sector

The pharmaceutical industry is constantly evolving, with technology playing a crucial role in transforming drug discovery, development, and delivery to patients worldwide. Technology plays a pivotal role in shaping the pharmaceutical sector globally. Let's delve into some key aspects:

Technology is revolutionizing drug development through R&D, precision medicine, and biotechnology. Advanced computational models, AI, and machine learning aid in drug discovery, target identification, and chemical structure optimization. Precision medicine uses genomics and proteomics for personalized treatment, while biotechnology contributes to the existence of monoclonal antibodies and gene therapies. Approximately 800 companies worldwide are involved in AI-driven drug discovery.

Automation in drug manufacturing improves efficiency and reduces human error, while technology ensures stringent quality standards, minimizes batch variations and ensures patient safety. Blockchain technology enhances supply chain transparency, traceability, and security, while cold chain management technology monitors temperature-sensitive drugs during transportation and storage.

Image source: Cold chain management

Electronic Health Records (EHRs) and Real-World Evidence (RWE) aid in data collection and analysis during clinical trials, while technology uses real-world patient data to inform drug efficacy and safety. The Health Technology Assessment evaluates new treatments' clinical and economic value, while digital health solutions like telemedicine and wearables enhance patient engagement.

Balancing innovation with affordability remains a challenge, but technology can enhance transparency and foster trust, while global collaboration is crucial for equitable access to medicines. Technology enhances innovation, efficiency, and accessibility in the pharmaceutical sector, ultimately benefiting patients worldwide.

Technological advancements in molecular and cell biology are revolutionising the pharmaceutical sector, enhancing understanding of disorders, promoting effective treatments, and improving health outcomes through improved drug discovery and patient care.

In summary, AI revolutionises drug discovery by improving accuracy, speed, and outcomes. AI is revolutionising drug discovery by enhancing efficiency, accuracy, and speed, paving the way for improved healthcare outcomes. Some global examples are Insilico Medicine,  Exscientia, DeepCure, CytoReason, Genome Biologics, Standigm, and Roivant Sciences.

Technology in the Slovenian Pharmaceutical Sector

Slovenia's pharmaceutical sector is significantly influenced by technology, which promotes innovation, efficiency, and enhanced patient outcomes. Here are some ways technology impacts the industry:

Novartis BioCampus in Mengeš: Novartis is investing EUR 111 million in the construction of the BioCampus in Mengeš, Slovenia, aiming to enhance early biotherapeutic development and strengthen its position as the first fully-fledged innovative medicines company in Slovenia.

Cleanroom Technological Solutions: Slovenian companies provide advanced cleanroom solutions for European pharmaceutical companies, ensuring controlled drug production environments and minimising contamination risks.

Processing Basic Chemicals: Slovenia's expertise in basic chemical processing is enhanced by the need for complex technologies and flexibility in meeting customer needs.

Image source: Big data analytics for drug discovery

Innovative Drug Discovery and Development: Technology like computational modelling, AI, and big data analytics are enhancing drug discovery by facilitating high-throughput screening and virtual simulations for potential drug candidates.

Biotechnology and Genomics: Biotechnology advancements enable the development of novel biologics and personalised medicine, while genomic research informs targeted therapies and precision medicine.

Digital Health Solutions: The integration of telemedicine, wearable devices, and health apps has significantly improved patient monitoring and engagement, while digital health platforms have enhanced disease management and treatment adherence.

Supply Chain Management: Technology enhances supply chain logistics, ensuring timely medication delivery, while blockchain enhances transparency and traceability.

Quality Control and Compliance: Automation and data analytics are transforming manufacturing processes, enhancing quality control and ensuring regulatory compliance.

Image source: IoT, Artificial Intelligence and Blockchain

Environmental Monitoring and Sustainability: Sensors and IoT devices are being utilised in production facilities to monitor environmental conditions, promoting sustainable practices to decrease waste and energy consumption.

Collaboration with Research Institutions: Slovenian pharmaceutical companies are partnering with academic and research institutions to foster innovation and knowledge exchange through joint research projects.

Slovenia's pharmaceutical industry is leveraging technology for efficiency, safety, and competitiveness, emphasising the significance of digital solutions and sustainable practices for global health impact.

AI in Successful Drug Discovery

Artificial Intelligence (AI) enhances drug discovery through:

Data Analysis: AI processes vast datasets, identifying potential drug candidates and predicting their efficacy.

Speed and Efficiency: AI accelerates the drug development timeline, reducing costs.

Target Identification: AI predicts novel drug targets, aiding in personalised medicine.

Image source: Precision Medicine

Precision Medicine: AI tailors treatments to individual patients based on genetic makeup.

Innovative Hypotheses: AI generates novel hypotheses for drug design.

Successful Examples of AI in Drug Discovery in Slovenia

Verge Genomics: Verge Genomics, an AI-powered company, has reported positive safety data from Phase 1 trials for its AI candidate in therapeutic development for ALS, with further announcements expected in 2024.

Lantern Pharma: Lantern Pharma has developed the RADR AI platform, which uses AI to predict drug responses and identify potential repurposing candidates, to accelerate drug development and improve patient outcomes.

Image source: Drug development

Deep Learning Algorithms: Deep learning algorithms, trained on drug compound datasets, can propose new therapeutic molecules with desired characteristics like solubility and activity, demonstrating the potential for rapid and efficient design of new drug candidates.

Collaboration with Research Institutions: Slovenian pharmaceutical companies are collaborating with academic and research institutions to drive innovation and knowledge exchange through joint research projects.

Predicting Drug Efficacy and Toxicity: AI-based methods are used to accurately predict the efficacy and toxicity of drug candidates, which significantly enhances decision-making during drug development.

The integration of AI technologies is significantly enhancing the advancements in pharmaceutical research and development in Slovenia.

AI Tools for Drug Discovery in Slovenia

Slovenia is utilizing AI tools for drug discovery through existing platforms, collaboration with research institutions, and exploring open-source resources. Here are some avenues for startups and researchers:

Collaborate with Research Institutions: Collaborate with universities, research centers, and academic labs to collaborate on AI-based drug discovery projects, leveraging expertise, data, and infrastructure.

Open-Source AI Tools: Explore open-source AI tools like AlphaFold, DeepChem, and Chemputer for drug discovery, which predict protein 3D structures, generate molecular leads, and report chemical synthesis procedures in standardised formats.

Image source: Cloud-based services in the pharmaceutical sector

Industry-Specific Platforms: Explore industry-specific platforms with AI-driven drug discovery capabilities, some of which offer cloud-based services, making them accessible to startups and researchers.

Collaborate with Established Companies: Collaborate with pharmaceutical companies or AI-driven startups to collaborate on joint projects or explore licensing opportunities.

Participate in Data-Thons and Hackathons: Participate in drug discovery-focused data-thons or hackathons, which provide access to AI tools, datasets, and mentorship.

Stay Informed and Network: Engage in conferences, workshops, and webinars on AI in drug discovery to connect with experts, practitioners, and fellow researchers. 

Apply for Grants and Funding:  Securing grants or funding from government agencies, foundations, or private organisations to aid AI research and tool development should be explored.

In Slovenia, the effective use of AI tools for drug discovery relies heavily on collaboration, continuous learning, and resource utilisation.

Drug Safety Assessment During Development in Slovenia

The use of Artificial Intelligence (AI) has the potential to significantly improve drug safety assessment during the development process in Slovenia. Let's explore some ways AI can contribute:

Predictive Toxicology: AI models predict drug toxicity based on chemical properties, identifying safety risks early in drug development by analysing molecular structures and historical toxicity data.

Image source: COVID-19

Adverse Event Prediction: AI can utilise real-world data, including electronic health records and adverse event reports, to identify patterns and predict potential drug-related adverse effects.

Drug-Drug Interactions (DDIs): AI algorithms are used to analyse drug properties and known interactions to prevent harmful combinations between different drugs.

Pharmacovigilance: AI is enhancing drug safety monitoring post-market approval by detecting unusual patterns, signals, and adverse events from large datasets. 

Early Detection of Safety Signals: AI is utilised in clinical trial data analysis to detect safety signals and identify specific adverse events for further investigation.  

Image source: Patient care

Patient Stratification: AI can identify patient groups at higher risk of adverse reactions, improving patient outcomes through personalised safety assessments.

Drug Repurposing: AI is identifying existing drugs with potential safety profiles for new indications while repurposed drugs undergo faster safety assessments.

Automated Literature Review: AI is utilised to conduct a safety analysis of scientific literature, ensuring researchers remain informed about emerging safety concerns.

Explainable AI (XAI): AI models can be interpreted, enhancing trust and safety assessment by providing a deeper understanding of model decisions.

Collaboration with Regulatory Authorities: AI-driven safety assessments comply with regulatory requirements, expediting approvals through collaboration and ensuring compliance with safety standards.  

Slovenia is utilising AI to enhance safety assessment, minimise risks, and improve drug development safety.

ALSO READ: Indian Pharmaceutical Industry in 2024


Slovenia's pharmaceutical sector is thriving, with collaborations, research advancements, and market expansion from established players and foreign companies. Balancing cost containment and innovation is crucial for long-term sustainability, involving R&D, innovative therapies, and regulatory frameworks that promote innovation without compromising affordability.

Slovenia's pharmaceutical industry holds significant potential to improve healthcare outcomes and enhance lives, with a positive outlook emphasising the need for cost containment and innovation. While the Slovenian Industrial Strategy 2021–2030 strategy doesn’t exclusively target the pharmaceutical industry, its overarching principles apply to all sectors, including healthcare and pharmaceuticals. 

Slovenia’s commitment to sustainability aligns with global efforts to create a more resilient and environmentally conscious industry. However, the ethical considerations of AI in healthcare need focus as the field is developing at a pace faster than what the professionals can handle.

Usha Menon

With over 25 years of experience as an architect, urban designer, and green building consultant, Usha has been designing sustainable, and visionary spaces. She has published a book, has been actively blogging, and is on social media. Now, her journey is transitioning to full-time writing. Her words will continue to craft stories, not brick and mortar, but in the realm of ideas, fostering a better, more inspired world.

Leave a Reply

Your email address will not be published.

Latest from Brown News